These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 33579427)

  • 1. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
    Sirica AE; Strazzabosco M; Cadamuro M
    Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
    Sirica AE; Gores GJ; Groopman JD; Selaru FM; Strazzabosco M; Wei Wang X; Zhu AX
    Hepatology; 2019 Apr; 69(4):1803-1815. PubMed ID: 30251463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matricellular proteins in intrahepatic cholangiocarcinoma.
    Sirica AE
    Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
    Ravichandra A; Bhattacharjee S; Affò S
    Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
    J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
    Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
    Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumour microenvironment and immune milieu of cholangiocarcinoma.
    Fabris L; Perugorria MJ; Mertens J; Björkström NK; Cramer T; Lleo A; Solinas A; Sänger H; Lukacs-Kornek V; Moncsek A; Siebenhüner A; Strazzabosco M
    Liver Int; 2019 May; 39 Suppl 1(Suppl 1):63-78. PubMed ID: 30907492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
    Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
    Cancer Lett; 2024 Jul; 594():216992. PubMed ID: 38797231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
    Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
    Cigliano A; Gigante I; Serra M; Vidili G; Simile MM; Steinmann S; Urigo F; Cossu E; Pes GM; Dore MP; Ribback S; Milia EP; Pizzuto E; Mancarella S; Che L; Pascale RM; Giannelli G; Evert M; Chen X; Calvisi DF
    J Exp Clin Cancer Res; 2024 Sep; 43(1):253. PubMed ID: 39243039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest.
    Mancarella S; Gigante I; Pizzuto E; Serino G; Terzi A; Dituri F; Maiorano E; Vincenti L; De Bellis M; Ardito F; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2024 Oct; 43(1):286. PubMed ID: 39415286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    Carpino G; Cardinale V; Di Giamberardino A; Overi D; Donsante S; Colasanti T; Amato G; Mennini G; Franchitto M; Conti F; Rossi M; Riminucci M; Gaudio E; Alvaro D; Mancone C
    J Hepatol; 2021 Dec; 75(6):1377-1386. PubMed ID: 34329660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.